August 30, 2016; 87 (9 Supplement 2) Article
Pediatric multiple sclerosis
Escalation and emerging treatments
Tanuja Chitnis, Angelo Ghezzi, Barbara Bajer-Kornek, Alexey Boyko, Gavin Giovannoni, Daniela Pohl
First published August 29, 2016, DOI: https://doi.org/10.1212/WNL.0000000000002884
Tanuja Chitnis
From Partners Pediatric MS Center (T.C.), Massachusetts General Hospital, Harvard Medical School, Boston; Divisione di Neurologia 2–Centro Studi Sclerosi Multipla (A.G.), Ospedale di Gallarate, Italy; Department of Neurology (B.B.-K.), Medical University of Vienna, Austria; Department of Neurology, Neurosurgery and Medical Genetics (A.B.), Pirogov's Russian National Research Medical University, Moscow; Barts and The London School of Medicine and Dentistry (G.G.), London, UK; and Department of Neurology (D.P.), Children's Hospital of Eastern Ontario, University of Ottawa, Canada.
Angelo Ghezzi
From Partners Pediatric MS Center (T.C.), Massachusetts General Hospital, Harvard Medical School, Boston; Divisione di Neurologia 2–Centro Studi Sclerosi Multipla (A.G.), Ospedale di Gallarate, Italy; Department of Neurology (B.B.-K.), Medical University of Vienna, Austria; Department of Neurology, Neurosurgery and Medical Genetics (A.B.), Pirogov's Russian National Research Medical University, Moscow; Barts and The London School of Medicine and Dentistry (G.G.), London, UK; and Department of Neurology (D.P.), Children's Hospital of Eastern Ontario, University of Ottawa, Canada.
Barbara Bajer-Kornek
From Partners Pediatric MS Center (T.C.), Massachusetts General Hospital, Harvard Medical School, Boston; Divisione di Neurologia 2–Centro Studi Sclerosi Multipla (A.G.), Ospedale di Gallarate, Italy; Department of Neurology (B.B.-K.), Medical University of Vienna, Austria; Department of Neurology, Neurosurgery and Medical Genetics (A.B.), Pirogov's Russian National Research Medical University, Moscow; Barts and The London School of Medicine and Dentistry (G.G.), London, UK; and Department of Neurology (D.P.), Children's Hospital of Eastern Ontario, University of Ottawa, Canada.
Alexey Boyko
From Partners Pediatric MS Center (T.C.), Massachusetts General Hospital, Harvard Medical School, Boston; Divisione di Neurologia 2–Centro Studi Sclerosi Multipla (A.G.), Ospedale di Gallarate, Italy; Department of Neurology (B.B.-K.), Medical University of Vienna, Austria; Department of Neurology, Neurosurgery and Medical Genetics (A.B.), Pirogov's Russian National Research Medical University, Moscow; Barts and The London School of Medicine and Dentistry (G.G.), London, UK; and Department of Neurology (D.P.), Children's Hospital of Eastern Ontario, University of Ottawa, Canada.
Gavin Giovannoni
From Partners Pediatric MS Center (T.C.), Massachusetts General Hospital, Harvard Medical School, Boston; Divisione di Neurologia 2–Centro Studi Sclerosi Multipla (A.G.), Ospedale di Gallarate, Italy; Department of Neurology (B.B.-K.), Medical University of Vienna, Austria; Department of Neurology, Neurosurgery and Medical Genetics (A.B.), Pirogov's Russian National Research Medical University, Moscow; Barts and The London School of Medicine and Dentistry (G.G.), London, UK; and Department of Neurology (D.P.), Children's Hospital of Eastern Ontario, University of Ottawa, Canada.
Daniela Pohl
From Partners Pediatric MS Center (T.C.), Massachusetts General Hospital, Harvard Medical School, Boston; Divisione di Neurologia 2–Centro Studi Sclerosi Multipla (A.G.), Ospedale di Gallarate, Italy; Department of Neurology (B.B.-K.), Medical University of Vienna, Austria; Department of Neurology, Neurosurgery and Medical Genetics (A.B.), Pirogov's Russian National Research Medical University, Moscow; Barts and The London School of Medicine and Dentistry (G.G.), London, UK; and Department of Neurology (D.P.), Children's Hospital of Eastern Ontario, University of Ottawa, Canada.
Pediatric multiple sclerosis
Escalation and emerging treatments
Tanuja Chitnis, Angelo Ghezzi, Barbara Bajer-Kornek, Alexey Boyko, Gavin Giovannoni, Daniela Pohl
Neurology Aug 2016, 87 (9 Supplement 2) S103-S109; DOI: 10.1212/WNL.0000000000002884
Citation Manager Formats
Make Comment
See Comments

Article Figures & Data
Tables
Letters: Rapid online correspondence
No comments have been published for this article.
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
- Article
- Abstract
- GLOSSARY
- CONCEPTUAL APPROACHES TO TREATING CHILDREN WITH MS
- SHORT- AND LONG-TERM CONSEQUENCES OF PEDIATRIC MS
- INADEQUATE TREATMENT RESPONSE TO INITIAL THERAPY
- CURRENT KNOWLEDGE ON SECOND-LINE TREATMENTS IN PEDIATRIC MS
- CONCEPTS AROUND EMERGING CLINICAL TRIALS OF NOVEL AGENTS IN PEDIATRIC MS
- VIEW TO FUTURE APPROACHES TO THERAPY WITH CURRENTLY AVAILABLE AND EMERGING KNOWLEDGE OF THERAPEUTICS IN PEDIATRIC MS
- AUTHOR CONTRIBUTIONS
- STUDY FUNDING
- DISCLOSURE
- Footnotes
- REFERENCES
- Figures & Data
- Info & Disclosures
Advertisement
Use of Whole-Genome Sequencing for Mitochondrial Disease Diagnosis
Dr. Robert Pitceathly and Dr. William Macken
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Articles
Treatment of pediatric multiple sclerosis and variantsD. Pohl, E. Waubant, B. Banwell et al.Neurology, April 16, 2007 -
Article
Clinical trials of disease-modifying agents in pediatric MSOpportunities, challenges, and recommendations from the IPMSSGEmmanuelle Waubant, Brenda Banwell, Evangeline Wassmer et al.Neurology, May 01, 2019 -
Article
Pediatric multiple sclerosisClinical features and outcomeAmy Waldman, Jayne Ness, Daniela Pohl et al.Neurology, August 29, 2016 -
Views & Reviews
International Pediatric MS Study Group Clinical Trials SummitMeeting reportTanuja Chitnis, Marc Tardieu, Maria Pia Amato et al.Neurology, March 18, 2013